Table 3.
IPA highest ranked canonical pathways
| Ingenuity canonical pathways | Analysis name | Ratio | P-value | Molecules |
|---|---|---|---|---|
| (A) Significantly altered in WKY but not SHR | ||||
| Nitric Oxide Signaling in the Cardiovascular System | WKY | 0.050 | 0.000 | PRKAR2B,PLN,GUCY1A3,SLC7A1,ATP2A3 |
| Nitric Oxide Signaling in the Cardiovascular System | SHR | 0.020 | 0.091 | ITPR3,ATP2A2 |
| IL-1 Signaling | WKY | 0.047 | 0.001 | GNB1,FOS,JUN,PRKAR2B,ADCY6 |
| IL-1 Signaling | SHR | 0.019 | 0.117 | GNG11,GNB2 |
| TGF-β Signaling | WKY | 0.045 | 0.003 | FOS,JUN,TGFB3,SERPINE1 |
| TGF-β Signaling | SHR | NA | NA | |
| Renin–Angiotensin Signaling | WKY | 0.040 | 0.001 | FOS,JUN,PRKAR2B,ADCY6,AGT |
| Renin–Angiotensin Signaling | SHR | 0.016 | 0.154 | ITPR3,AGTR1 |
| (B) Significantly altered in SHR but not WKY | ||||
| Mitochondrial Dysfunction | SHR | 0.040 | 0.000 | NDUFS7,XDH,COX8A,COX7A2L,APP,NDUFB2,NDUFB10 |
| Mitochondrial Dysfunction | WKY | 0.017 | 0.079 | NDUFS5,COX8A,TXNRD2 |
| Insulin Receptor Signaling | SHR | 0.036 | 0.001 | RPS6KB1,BAD,EIF2B3,GSK3B,PPP1CA |
| Insulin Receptor Signaling | WKY | 0.014 | 0.254 | PRKAR2B,EIF4EBP1 |
ADCY6, adenylate cyclase 6; AGT, angiotensinogen; AGTR1, angiotensin II receptor, type 1; APP, amyloid beta (A4) precursor protein; ATP2A2, ATPase, Ca++ transporting, cardiac muscle, slow twitch 2; ATP2A3, ATPase, Ca++ transporting, ubiquitous; BAD, BCL2-associated agonist of cell death; COX7A2L, cytochrome c oxidase subunit VIIa polypeptide 2 like; COX8A, cytochrome c oxidase subunit VIIIa; EIF2B3, eukaryotic translation initiation factor 2B, subunit 3; EIF4EBP1, eukaryotic translation initiation factor 4E-binding protein 1; FOS, FBJ osteosarcoma oncogene; GNB1, guanine nucleotide-binding protein (G protein), beta polypeptide 1; GNB2, guanine nucleotide-binding protein (G protein), beta polypeptide 2; GNG11, guanine nucleotide-binding protein (G protein), gamma 11; GSK3B, glycogen synthase kinase 3 beta; GUCY1A3, guanylate cyclase 1, soluble, alpha 3; ITPR3, inositol 1,4,5-trisphosphate receptor, type 3; JUN, jun proto-oncogene; NDUFB10, NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 10; NDUFB2, NADH dehydrogenase (ubiquinone) 1 beta subcomplex, 2; NDUFS5, NADH dehydrogenase (ubiquinone) Fe-S protein 5; NDUFS7, NADH dehydrogenase (ubiquinone) Fe-S protein 7; PLN, phospholamban; PPP1CA, protein phosphatase 1, catalytic subunit, alpha isozyme; PRKAR2B, protein kinase, cAMP dependent regulatory, type II beta; PRKAR2B, protein kinase, cAMP dependent regulatory, type II beta; PRKAR2B, protein kinase, cAMP dependent regulatory, type II beta; RPS6KB1, ribosomal protein S6 kinase, polypeptide 1; SERPINE1, serpin peptidase inhibitor, clade E (nexin, plasminogen activator inhibitor type 1), member 1; SLC7A1, solute carrier family 7 (cationic amino acid transporter, y+ system), member 1; TGFB3, transforming growth factor, beta 3; TXNRD2, thioredoxin reductase 2; XDH, xanthine dehydrogenase. IPA, Ingenuity® pathway analysis; WKY, Wistar Kyoto; SHR, spontaneously hypertensive rat; IL, interleukin; TGF, transforming growth factor.